Eisai
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
July 31, 2024Research and Development Alzheimers, Conference results, Eisai, Neurology
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …
Eisai and EcoNaviSta enter dementia collaboration
July 25, 2024Business Services EcoNaviSta, Eisai, Neurology, collaboration, dementia
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
Eisai shares new data for Leqembi for Alzheimer’s treatment
October 26, 2023Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …
Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies
December 1, 2020Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Wren Therapeutics
Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in tackling neurodegenerative diseases known as …
Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis
September 25, 2020Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca
Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …
New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda
New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …
Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer
February 17, 2020Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma
New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …
Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk
February 14, 2020Medical Communications, Research and Development, Sales and Marketing Belviq, Eisai, FDA, pharma
The FDA has requested that Eisai withdraw its weight loss drug Belviq (lorcaserin) and Belviq XR from the US market …
Scottish Medicines Consortium recommends Eisai’s Kisplyx for advanced kidney cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Eisai, Kisplyx, NHS, Sotland, pharma
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the …
China approves Eisai’s Fycompa for partial onset epileptic seizures
October 16, 2019Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma
Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Biogen and Eisai discontinue Phase 3 Alzheimer’s trial
March 21, 2019Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health
Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …
